A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Authors:

Abstract
9077 Background: Pemetrexed (Pem) + Cisplatine (Cis) + Bevacizumab (Bev) followed with maintenance therapy (Bev and/or Pem) is a therapeutic standard in advanced non-squamous NSCLC. Methods: A single arm phase II trial aimed to evaluate a stop and go strategy: Sequence 1: 3 cycles Pem 500 mg/m² + Cis 75 mg/m² + Bev 7.5 mg/kg q3 weeks, followed by maintenance Bev 7.5 mg/kg/3 week until progression ; sequence 2: reintroduction Pem + Cis + Bev, 3 cycles, Pem + Bev maintenance until progression. Primary endpoint: at least 75% of patients in the sequence 2 received the 3 cycles without cisplatin/carboplatin dose modification. Results: from Dec. 2012 to Aug. 2014, 120 patients (77 males) were included in 14 French hospitals: PS 0 (50%); median age 60.6 y (36.0 – 77.3). Of 113 eligible patients, 65 (57.5 %) were treated in sequence 2. 37 patients (56.9%, IC95% [45.1%-73.6%]) received the 3 cycles (sequence 2) at full dose; 86 % (n = 56) with or without dose reduction. At sequence 2, specific bev-induced grade 3 – 4 toxicity was reported in 7 (10.3%) patients (1 grade 5 haemoptysis). Median follow-up was 27.1m [24.7-29.6]. Secondary objectives showed a median Progression-Free Survival 1 (PFS1) (inclusion – progression 1) 5.8 m (IC95%:5.0 – 6.3); median PFS2 (progression 1 – progression 2) 6.6 m (IC95%:5.7 – 8.4); median duration of disease control (PFS1 + PFS 2) (n = 65) 11.4 m (IC95:10.1 – 13.4). Objective response rate after sequence 2 was 15.4% (IC95%: 6.6-24.2) with 60% of stable disease. The median overall survival for eligible population was 17.7 m (IC95% 13.1 – 21.6) and 20.5 m (16.9 – NR) for patients who reached the sequence 2 (n = 65). Conclusions: Although the stringent primary endpoint was not met, this study highlighted that a ‘stop and go’ strategy using a platinum-based chemotherapy with bevacizumab continuation beyond progression, compares favourably with standard schedule, deserving to be further studied in non-squamous advanced NSCLC. Clinical trial information: NCT01705184.